Evidence map›Paper›PMID 37450776›Full record

ArticleJCO oncology practice2023

Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions.

Sofia I Jacobson, Alec J Kacew, Randall W Knoebel, Po-Hung Hsieh, Mark J Ratain, Garth W Strohbehn

Open access · greenAbstract read
In one paragraph

Article in JCO oncology practice, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Improving the Dosing Schedules of Targeted Anticancer Agents.Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  6. Article
  7. It is time to consider the climate crisis in haematology.Clinical hematology international · 2025
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Sofia I JacobsonYale College, New Haven, CT.ORCID 0009-0008-5120-1087
Alec J KacewUniversity of Chicago Pritzker School of Medicine, Chicago, IL.ORCID 0000-0002-0454-0376
Randall W KnoebelDepartment of Pharmacy, University of Chicago, Medicine, Chicago, IL.ORCID 0000-0002-0166-4955
Po-Hung HsiehCommittee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL.ORCID 0000-0003-1744-4815
Mark J RatainCommittee on Clinical Pharmacology and Pharmacogenomics, University of Chicago, Chicago, IL.ORCID 0000-0002-0938-4392
Garth W StrohbehnUniversity of Michigan Rogel Cancer Center, Ann Arbor, MI.ORCID 0000-0003-2973-3040
University of Chicago · USUnited States Food and Drug Administration · USUniversity of Michigan · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCancer care-related greenhouse gas (GHG) emissions harm human health. Many cancer drugs are administered at greater-than-necessary doses, frequencies, and durations. Alternative dosing strategies may enable reductions in cancer care GHG emissions without compromising patient outcomes. MATERIALS AND

methodsWe used streamlined life-cycle analysis in a case-control simulation to estimate the relative reductions in GHG emissions that would be expected to result from using each of three alternative dosing strategies of trastuzumab (6-month adjuvant treatment duration, once every 4-week dosing, and both) in human epidermal growth factor receptor 2 (HER2)+ breast cancer. Using primary data and conversion factors from the environmental science literature, we estimated per-patient relative reduction in GHG emissions and, using SEER data, health impacts (in terms of disability-adjusted life-years [DALYs] and excess mortality per kg CO

resultsCompared with the trastuzumab dosing strategy commonly used at baseline (12-month duration of adjuvant therapy and once every 3-week dosing in all settings), adoption of both 6-month adjuvant trastuzumab and once every 4-week trastuzumab dosing would reduce GHG emissions by 4.5%, 18.7%, and 14.6% in the neoadjuvant, adjuvant, and metastatic settings, respectively. We estimate that US-based adoption of alternative trastuzumab dosing would reduce annual DALYs and excess lives lost due to environmental impact of US-based trastuzumab therapy for HER2+ breast cancer by 1.5 and 0.9, respectively.

conclusionAlternative dosing strategies may materially reduce the population health impacts of cancer care by reducing environmental impact. Regulatory decision making and health technology assessments should consider a treatment's environmental and population health impacts. Clinical trials of alternative dosing strategies are justified on the basis of environmental and population health impacts.

Indexed as

Breast NeoplasmsGreenhouse GasesDelivery of Health CareFemaleGreenhouse EffectHumansTrastuzumabGreenhouse GasesTrastuzumab

Identifiers

PMID37450776
PMCPMC10538895
OpenAlexW4384296679

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.